Please login to the form below

Not currently logged in
Email:
Password:

Akarna Therapeutics

This page shows the latest Akarna Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a

Latest news

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    Allergan buys two NASH drug developers in one day. More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics. ... Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH)

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Closing on the same day as the Tobira deal, Allergan also paid $50m upfront with milestones to follow to buy Akarna Therapeutics, bringing AKN-083, a preclinical farnesoid X receptor (FXR) ... 639. Cynapsus Therapeutics / Sunovion. Acquisition corporate.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    Enterprise Therapeutics appoints CEO. Dr John Ford will lead the UK drug discovery company. ... Previously, Dr Ford has worked as general manager of Akarna Therapeutics' UK operations, chief operating officer of Dezima Pharma and a team leader for

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics